We provide you with 20 years of free, institutional-grade data for ANRO stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ANRO. Explore the full financial landscape of ANRO stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Smith Nicholas Conrad | Sale | -2,806 | $19.69 | $55,250 | 2026-03-03 |
| Etkin Amit | Sale | -6,227 | $19.69 | $122,610 | 2026-03-03 |
| Savitz Adam | Open Market Purchase | 15,000 | $12.53 | 2024-07-11 | |
| Smith Nicholas Conrad | Open Market Purchase | 6,150 | $15.8 | 2024-04-01 | |
| Etkin Amit | Grant, award...etc | 34,711 | 2024-03-05 | ||
| Smith Nicholas Conrad | Grant, award...etc | 19,153 | 2024-03-05 |
The information provided in this report about ANRO stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Alto Neuroscience Inc(NYSE:ANRO) 
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatone...
Website: https://altoneuroscience.com/
Founded: 2019
CEO / Founder: Amit Etkin
Sector: TECHNOLOGY
Industry: GENERAL
Share this website to your friends